FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, immunology and virology. What is described is an intranasal vaccine based on virus-like particles consisting of a mixture of virus-like particles and a pharmaceutically acceptable buffer. Virus-like particles consist of four structural proteins S, M, N, E SARS-CoV-2, where S protein is selected from versions 19A, Alpha, Delta, Omicron SARS-CoV-2. A method for preventing COVID-19 has also been developed, involving intranasal introduction of the vaccine three times with an interval between injections of 21 days.
EFFECT: group of inventions provides creating an intranasal vaccine having immunogenicity sufficient to generate an immune response against COVID-19, ability to induce humoral and cellular immune response, stimulate protective immunity of mucous membranes, as well as having an additional advantage of ease of administration compared to injectable forms.
4 cl, 3 dwg, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VIRUS-LIKE CHIMERIC PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 CONTAINING CORONAVIRUS AND ROTAVIRUS PROTEINS | 2022 |
|
RU2779810C1 |
| RECOMBINANT VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 | 2021 |
|
RU2769224C1 |
| IMMUNOBIOLOGICAL AGENT BASED ON VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST INFECTION CAUSED BY HUMAN ROTAVIRUS A | 2022 |
|
RU2795055C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS | 2014 |
|
RU2685185C2 |
| METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
